The role of anthracyclines in small cell lung cancer. - Wikidata - awgldk - TriplyDB

The role of anthracyclines in small cell lung cancer.

The role of anthracyclines in small cell lung cancer.

http://www.wikidata.org/entity/Q34358063

about

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells Crystal structure and conformational analysis of doxorubicin nitrate.

P2860

Q35673936-FC93703B-0076-463D-AD4B-7478542DA8EE Q38549648-F0FC6C1B-A2D3-4303-B5A3-226B2A3D1E11 Q55245438-3C056801-9B50-43A0-AEF4-AA463ABFECDD

P2860

The role of anthracyclines in small cell lung cancer.

http://www.wikidata.org/entity/Q34358063

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The role of anthracyclines in small cell lung cancer.

@ast

The role of anthracyclines in small cell lung cancer.

@en

The role of anthracyclines in small cell lung cancer.

@nl

type

label

The role of anthracyclines in small cell lung cancer.

@ast

The role of anthracyclines in small cell lung cancer.

@en

The role of anthracyclines in small cell lung cancer.

@nl

prefLabel

The role of anthracyclines in small cell lung cancer.

@ast

The role of anthracyclines in small cell lung cancer.

@en

The role of anthracyclines in small cell lung cancer.

@nl

P1433

Q34358063-C06B5A69-57A5-441B-836D-9F433DF89F05

P1476

Q34358063-EEBC48BE-78F2-418C-BB02-67BCD2FED0B8

P2093

Q34358063-24F15AFD-6E2B-4B2F-BB25-4074E740B142

Q34358063-26BD4A7A-C577-4DE4-A34A-65490CDD17FC

Q34358063-AAC1EF92-688F-4C71-B0E4-79F25B94F942

Q34358063-E887959F-77CB-4F06-A468-7FC364A1A30B

Q34358063-EDF3E564-9958-47F1-A61D-A148FDA52C08

P2860

Q34358063-26A64873-8A09-43BD-B76B-82B519192411

Q34358063-2E8DA2BF-F9D0-48E9-850C-6747554E1AC7

Q34358063-3996D9EF-28F9-471D-93FA-3D1026508B5B

Q34358063-3E3BCC39-07E0-4476-A164-62B17FEC8F22

Q34358063-426857FA-024D-4B74-9A2E-7C4457F2DE0E

Q34358063-45FE1EA4-3F78-424D-8018-BD3B757915F1

Q34358063-647878CD-2A0C-4535-8928-FF9E90C4A05F

Q34358063-6BD12471-8D52-4D2F-AA56-C8EBAE572E6F

Q34358063-6E80E716-009D-41B9-88CF-F4A2323C29B6

Q34358063-70720549-4FB1-4776-BF6F-D7A5DD1B09DB

P304

Q34358063-FE5CA3BC-3B36-4E7F-96E3-64F986C46470

P31

Q34358063-30C5293E-F64B-426F-B4CD-13CCE6CDF7A3

P356

Q34358063-EA6593BA-A35D-4EF3-B9DD-1083E9255B3F

P433

Q34358063-411EEB24-8437-4454-86EC-53625EF6509F

P478

Q34358063-59A861CE-515B-4B71-A5BB-7003453A9015

P50

Q34358063-A84F444C-D88C-4826-BAD6-38D8DF8D3DC9

P577

Q34358063-FD4AB158-7598-42FD-8E5A-7982098FA124

P698

Q34358063-D64DB17D-B385-4EF3-A021-215FFEA3D2A5

P932

Q34358063-870D8658-E1CF-498A-ADFD-B62AE12BAFF1

P356

J.ISSN.2305-5839.2013.01.05

P1433

Annals of translational medicine

P1476

The role of anthracyclines in small cell lung cancer.

@en

P2093

Ana López-González

http://www.w3.org/2001/XMLSchema#string

Andrés García Palomo

http://www.w3.org/2001/XMLSchema#string

Elena Almagro

http://www.w3.org/2001/XMLSchema#string

Lourdes Gutierrez

http://www.w3.org/2001/XMLSchema#string

Pilar Diz

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy versus best supportive care for extensive small cell lung cancer

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2305-5839.2013.01.05

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Mariano Provencio

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25332950

http://www.w3.org/2001/XMLSchema#string

P932

4200693

http://www.w3.org/2001/XMLSchema#string